GlassScriptPhysician profile
Tabarak A Qureshi
NPI 1962674549
$205,928.02
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $38K · 2021: $83K · 2022: $40K · 2023: $52.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $52.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $52.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $92,778.34 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $59,429.45 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $47,831.62 | 2019-2022 | |
| Ethicon INC. | $962.48 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $854.44 | 2019-2022 | |
| Pulmonx Corporation | $804.83 | 2019-2022 | |
| Glaxosmithkline, LLC. | $349.48 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.58 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $263.24 | 2019-2020 | |
| Harmony Biosciences LLC | $244.18 | 2020-2022 | |
| Philips North America LLC | $155.19 | 2019-2020 | |
| Genentech USA, INC. | $148.96 | 2019 | |
| United Therapeutics Corporation | $136.28 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $132.66 | 2019-2021 | |
| Gilead Sciences, INC. | $126.59 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $122.34 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.13 | 2021-2022 | |
| Inspire Medical Systems, INC. | $121.91 | 2022 | |
| Ucb, INC. | $118.10 | 2019-2021 | |
| Veran Medical Technologies, INC. | $115.74 | 2019-2020 | |
| Mylan Specialty L.P. | $115.49 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $106.30 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $99.76 | 2021 | |
| Insmed, INC. | $80.82 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $80.60 | 2021-2022 | |
| Grifols USA, LLC | $74.75 | 2019-2022 | |
| Amgen INC. | $48.85 | 2022 | |
| Allergan, INC. | $30.79 | 2019 | |
| Portola Pharmaceuticals, LLC | $28.30 | 2019 | |
| Fisher & Paykel Healthcare INC | $27.79 | 2021-2022 | |
| Advanced Respiratory, INC | $27.78 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $27.70 | 2019 | |
| Covis Pharma Gmbh | $24.76 | 2022 | |
| Baxter Healthcare | $23.63 | 2022 | |
| Shire North American Group INC | $22.49 | 2019 | |
| Paratek Pharmaceuticals, INC. | $12.67 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabarak Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.